Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.
[erythropoietic protoporphyria]
The
selenoprotein
thioredoxin
reductase
1
(
TrxR
1
)
has
in
recent
years
been
identified
as
a
promising
anticancer
drug
target
.
A
high
-throughput
assay
for
discovery
of
novel
compounds
targeting
the
enzyme
is
therefore
warranted
.
Herein
,
we
describe
a
single
-enzyme
,
dual-purpose
assay
for
simultaneous
identification
of
inhibitors
and
substrates
of
TrxR
1
.
Using
this
assay
to
screen
the
LOPAC
¹²â¸â°
compound
collection
we
identified
several
known
inhibitors
of
TrxR
1
,
thus
validating
the
assay
,
as
well
as
several
compounds
hitherto
unknown
to
target
the
enzyme
.
These
included
rottlerin
(
previously
reported
as
a
PKCδ
inhibitor
and
mitochondrial
uncoupler
)
and
the
heme
precursor
protoporphyrin
IX
(
PpIX
)
.
We
found
that
PpIX
was
a
potent
competitive
inhibitor
of
TrxR
1
,
with
a
K
(
i
)
=
2
.
7
μM
with
regard
to
Trx
1
,
and
in
the
absence
of
Trx
1
displayed
time-dependent
irreversible
inhibition
with
an
apparent
second
-order
rate
constant
(
k
(
inact
)
)
of
(
0
.
73
±
0
.
07
)
×
10
â»
³
μM
â»
¹
min
â»
¹
.
Exogenously
delivered
PpIX
was
cytotoxic
,
inhibited
A
549
cell
proliferation
,
and
was
found
to
also
inhibit
cellular
TrxR
activity
.
Hemin
and
the
ferrochelatase
inhibitor
NMPP
also
inhibited
TrxR
1
and
showed
cytotoxicity
,
but
less
potently
compared
to
PpIX
.
We
conclude
that
rottlerin-induced
cellular
effects
may
involve
targeting
of
TrxR
1
.
The
unexpected
finding
of
PpIX
as
a
TrxR
1
inhibitor
suggests
that
such
inhibition
may
contribute
to
symptoms
associated
with
conditions
of
abnormally
high
PpIX
levels
,
such
as
reduced
ferrochelatase
activity
seen
in
erythropoietic
protoporphyria
.
Finally
,
additional
inhibitors
of
TrxR
1
may
be
discovered
and
further
characterized
based
upon
the
new
high
-throughput
TrxR
1
assay
presented
here
.
Diseases
Validation
Diseases presenting
"such as reduced ferrochelatase activity seen in erythropoietic protoporphyria"
symptom
erythropoietic protoporphyria
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom